Project description
A pioneering screening tool for early detection of bladder cancer could save millions
The difference between early and late diagnosis of cancer can mean the difference between life and death. Unlike a routine PAP test for cervical cancer or a colonoscopy for colon cancer, there is currently no effective screening tool for bladder cancer and late diagnosis can have lethal consequences. VISIOCYT has developed a simple software solution that evaluates standard clinical cytology slides. A proprietary method for preparation, staining and observation of cells is coupled with an image processing algorithm to detect the presence of localised fluorescence associated with malignancy. Deep learning algorithms allow the software to learn from the data without being explicitly programmed. EU funding is supporting commercialisation of this reproducible and high throughput technology for early bladder cancer detection.
Objective
Bladder cancer is the 5th most common cancer in Europe, with almost 200,000 new cases and 65,000 deaths estimated in 2018. People at high risk for developing this disease include smokers, former smokers, people living in polluted areas, and workers exposed to certain chemicals. The risk of dying from bladder cancer depends on the time of diagnosis and the tumour’s grade: the 5-year survival rate is >95% in early stage cancer, but it drops to <5% in late stage tumours. Besides increased survival, the identification of bladder cancer at its early stages is also associated with easier, less invasive, and cheaper treatment.
Given the importance of early detection and the high incidence of bladder cancer, screening programs for this disease are needed. However, there is no screening tool currently available for bladder cancer. As a solution, VitaDX is developing VisioCyt Screening: a software that combines artificial intelligence algorithms with standard cytology analysis to predict with high accuracy the presence of bladder cancer in patients, even before symptoms appear. Being a software that analyses images obtained through regular clinical procedures, VisioCyt Screening can be readily implemented in centralized labs, resulting in a fast, easy-to-use, reproducible, automated, and high-throughput solution at a low price.
VisioCyt Screening can be classified as an in-vitro diagnostic (IVD) medical device. The global IVD market was estimated at €58 billion in 2018, and is expected to reach €75.2 billion by 2023, with a CAGR rate of 5.2%. In this market, centralized laboratories, which perform large numbers of analyses in few locations and are equipped with the automated systems required by the VisioCyt solution, represent the most relevant target users and customers for VitaDX.
VitaDX is a French SME that combines a strong scientific and clinical background with software and image processing skills and business expertise to develop new diagnostic solutions for cancer.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences computer and information sciences artificial intelligence
- medical and health sciences clinical medicine oncology bladder cancer
- medical and health sciences clinical medicine urology
- medical and health sciences basic medicine pathology
- medical and health sciences basic medicine physiology cytology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
35000 RENNES
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.